Biotech investors love pipeline value, but most portfolio rankings still miss the point.
A company can have a long list of programs and still be quietly destroying valuebecause the timing and probability of cash flows are treated like afterthoughts. In…

The patent cliff isnt just a pharma problemits a talent problem.
Most people talk about the patent cliff as a revenue event: when exclusivity ends, generic competition arrives, margins compress, and pipelines suddenly look urgent. But theres another cl…

Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
Branded drug inventory risk isnt just a finance problemits a timing problem.
In wholesaling, the margin story can flip overnight when a branded product appr…

Big Pharma doesnt always announce its next workforce shift. Sometimes it whispersthrough patents.
Heres the hidden hiring signal many leaders miss: patent cliff events dont just reshape revenue forecasts. They reshape headcount decisions, contractor sp…

Biosimilar sourcing isnt a procurement problemits a patent strategy problem.
If youre planning a switch from an originator to a biosimilar, the hardest part usually isnt identifying candidates. Its timing the switch so you capture volume and margin bef…

Pharma has a new way to sell the same storyjust with a different price tag.
In a world where patients are increasingly asked to wait for innovation, drugmakers are finding another lever: repurposed medicines. The molecules may be old. The indication ma…

Pharma recruiting is broken in a very specific way: most teams still treat best scientists like a vibe instead of a measurable signal.
If youve ever watched a search committee chase the same handful of CV buzzwordspatent experience, publication record,…

Old Drugs. New Prices. The Pharma Playbook Is Getting Sharper.
Theres a quiet shift happening across healthcareone that rarely makes headlines, but shows up fast in pharmacy benefit managers, formularies, and patient out-of-pocket costs.
A growing numb…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russias third wheel rule is supposed to be a footnote in the global drug supply chain. In practice, its a signal flareone that can tell you where Russia is headed next in APIs, full-cycle manufacturing, and the next wave of patent battles.
Heres the ag…